Özlem Türeci focuses on Antigen, Immunology, Cancer, Antibody and Immune system. Her Antigen study integrates concerns from other disciplines, such as RNA, Molecular biology and Cytotoxic T cell. Her Cancer research includes themes of Autoantibody, Cancer research, Melanoma and Blood test.
The various areas that Özlem Türeci examines in her Melanoma study include Cancer/testis antigens and Northern blot. Immunogenicity is the focus of her Antibody research. Her Vaccination research incorporates elements of CD8 and Immunity.
Her primary areas of study are Cancer, Antigen, Cancer research, Immunology and Antibody. Her Cancer study which covers Oncology that intersects with CA15-3, Pancreatic cancer and Ovarian cancer. Her biological study spans a wide range of topics, including RNA, T cell, Immune system and Molecular biology.
Özlem Türeci works mostly in the field of Immune system, limiting it down to concerns involving Vaccination and, occasionally, Bioinformatics. Her research integrates issues of Pathology, Tight junction, Claudin, Colorectal cancer and In vivo in her study of Cancer research. Özlem Türeci studies Monoclonal antibody which is a part of Antibody.
Her main research concerns Cancer research, Cancer, Antibody, Antigen and Immunotherapy. Her work deals with themes such as Cell, Immune system, Claudin, Cytotoxic T cell and Chimeric antigen receptor, which intersect with Cancer research. Her Immune system research is under the purview of Immunology.
Her Cancer study typically links adjacent topics like Melanoma. Özlem Türeci combines subjects such as T cell, Severe acute respiratory syndrome coronavirus 2 and Virology, Vaccination with her study of Antibody. Özlem Türeci focuses mostly in the field of Antigen, narrowing it down to topics relating to RNA and, in certain cases, Coronavirus disease 2019.
Özlem Türeci spends much of her time researching Antibody, Vaccination, Immunology, RNA and Antigen. Her Antibody research focuses on Virology and how it connects with Severe acute respiratory syndrome coronavirus 2 and Coronavirus disease 2019. Her Vaccination research includes elements of T cell, CD8, Immune system, Immunization and Immunotherapy.
Her Immune system study combines topics in areas such as Cancer, Interim analysis and Melanoma. Her Immunology study combines topics from a wide range of disciplines, such as Tolerability and Pandemic. She has included themes like Cancer research and Tight junction in her RNA study.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates.
Edward E. Walsh;Robert W. Frenck;Ann R. Falsey;Ann R. Falsey;Nicholas Kitchin.
The New England Journal of Medicine (2020)
Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
Ugur Sahin;Evelyna Derhovanessian;Matthias Miller;Björn-Philipp Kloke.
A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening
Yao-Tseng Chen;Matthew J. Scanlan;Ugur Sahin;Özlem Türeci.
Proceedings of the National Academy of Sciences of the United States of America (1997)
Human neoplasms elicit multiple specific immune responses in the autologous host.
Ugur Sahin;Ozlem Tureci;Holger Schmitt;Bjorn Cochlovius.
Proceedings of the National Academy of Sciences of the United States of America (1995)
COVID-19 vaccine BNT162b1 elicits human antibody and T H 1 T cell responses.
Ugur Sahin;Alexander Muik;Evelyna Derhovanessian;Isabel Vogler.
mRNA-based therapeutics — developing a new class of drugs
Ugur Sahin;Katalin Karikó;Özlem Türeci.
Nature Reviews Drug Discovery (2014)
Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults.
Mark J. Mulligan;Kirsten E. Lyke;Nicholas Kitchin;Judith Absalon.
Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy
Lena M. Kranz;Mustafa Diken;Heinrich Haas;Sebastian Kreiter.
Mutant MHC class II epitopes drive therapeutic immune responses to cancer
Sebastian Kreiter;Mathias Vormehr;Niels van de Roemer;Mustafa Diken.
Exploiting the mutanome for tumor vaccination
John C. Castle;Sebastian Kreiter;Jan Diekmann;Martin Löwer.
Cancer Research (2012)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: